<DOC>
	<DOCNO>NCT00904826</DOCNO>
	<brief_summary>The purpose study determine drug eculizumab reduce attack rate improves outcome patient neuromyelitis optica .</brief_summary>
	<brief_title>An Open Label Study Effects Eculizumab Neuromyelitis Optica</brief_title>
	<detailed_description>It show scientific study antibody marker specific neuromyelitis optica ( NMO ) , know NMO-Immunoglobulin G ( IgG ) , cause inflammation brain tissue activate substance call complement . Complement greatly increase immune attack optic nerve ( cause optic neuritis ( ON ) ) , spinal cord ( cause transverse myelitis ( TM ) ) brain patient NMO . Eculizumab already show effective rare blood disorder know paroxysmal nocturnal hemoglobinuria ( PNH ) . Attacks PNH also mediate complement . Therefore , investigator study investigate whether 'turning ' complement NMO , attack NMO prevent . The primary ( important ) objective study determine : Whether Eculizumab reduce relapse frequency patient relapse NMO . The number attack one year treatment period compare number attack occur prior initiation eculizumab treatment . For patient 2 year disease duration , average number attack precede 2 year calculate . For patient le 2 year disease duration number attack precede year use . The safety profile eculizumab patient NMO . The secondary objective determine : Whether eculizumab maintain improves walk , visual function quality life measure variety establish disability scale . We also assess severity individual attack degree recovery . How drug behave patient 's blood ( call pharmacodynamics pharmacokinetics ) . Depending preliminary investigation may evaluate patient cerebrospinal fluid laboratory see effective eculizumab get cerebrospinal fluid blood stream , see drug revers biological effect NMO-IgG antibody .</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>1 . Diagnosis NMO , define 2006 criterion OR NMO seropositive spectrum disorder ( Recurrent ON longitudinally extensive transverse myelitis ( LETM ) ) . All patient must NMOIgG seropositive . 2 . Clinical evidence least 2 relapse last 6 month 3 relapse last 12 month ( least 1 relapse occur precede 6 month ) . 3 . Age â‰¥18 year 4 . Corrected visual acuity 20/100 good least one eye . If fails item # 4 entry allow last attack myelitis attack myelitis consider outcome measurement . 5 . Ambulatory ( without walker ) . If fails item # 5 entry allow last attack ON attack ON consider outcome measurement . 6 . Provision write informed consent ( see attach ) participate study . 7 . N. meningitidis vaccination least 14 day prior receive first eculizumab infusion . If patient midst acute relapse , relapse treat standard therapy vaccination give minimum 4 week post attack onset . Candidates exclude study entry follow criterion meet time randomization : 1 . Progressive neurological deterioration unrelated relapse ON myelitis . 2 . Pregnant , breastfeeding , intend conceive course study 3 . Patients participate clinical therapeutic study participate experimental treatment study within 30 day screen 4 . Patients history splenectomy , potential increase risk develop meningococcal infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>NMO</keyword>
	<keyword>Devic 's disease</keyword>
	<keyword>Neuromyelitis optica</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>Aquaporin-4 antibody</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>Complement</keyword>
</DOC>